Condition: Epilepsy, Temporal Lobe · Drug Resistant Epilepsy · Sponsor: Genovate-NaviFUS (Australia) Pty Ltd.
Participants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment with the NaviFUS System, guided by the neuronavigation system to evaluate the safety and efficacy of using NaviFUS System. During the treatment, the FUS will electronically scan and target to the assigned zones on one or both of the hippocampi. The study consists of a 60-day screening period for baseline observation prior to treatment, a FUS treatment period of 2 weeks for Cohort 1 or 3 weeks for Cohort 2 with 2 FUS treatments per week using the NaviFUS System, and a safety follow-up period of 81 days.
This description comes directly from the study's public registry record.
Caitlin Roberts, Ms. · +61 3 9076 2598 · cai.roberts@alfred.org.au
Jack Germaine, Mr. · +61 3 9076 2029 · j.germaine@alfred.org.au
Always discuss trial participation with your own doctor first.
| The Alfred | Melbourne, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05947656